• Теги
    • избранные теги
    • Компании2100
      • Показать ещё
      • Показать ещё
      Страны / Регионы441
      • Показать ещё
      Международные организации34
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
28 апреля, 17:31

AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates

AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.

28 апреля, 15:41

Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

Выбор редакции
28 апреля, 10:36

Will Lloyds chief enjoy plain sailing or will he jump ship? | Nils Pratley

Lloyds is riding high, but allure of global stage could prove enough to entice António Horta-Osório away from comfortable gigLloyds Banking Group’s bad and impaired loans stand at historically low levels. Its net interest margin – the best measure of a bank’s profitability – is the highest in the UK sector, and still rising. It is generating capital faster than expected. The end is in sight on PPI provisions. And the state’s stake has been reduced to 2%, with the last of the shares to be sold in coming weeks. A good moment, then, for chief executive António Horta-Osório to bow out after six years at the helm? Horta-Osório says he’s happy in his post and there is more to do. Not everybody is convinced by that answer, since six years counts as a long innings for a FTSE 100 chief executive and he’s constantly linked with the vacancy at HSBC. An exit can’t be ruled out. But, actually, committing to a couple more laps of the track at Lloyds is surely a highly attractive prospect. With a 25% share of the UK retail market, the bank is currently playing in a league of its own and can expect to do so for years. Continue reading...

Выбор редакции
Выбор редакции
27 апреля, 11:59

Европейски рынки акций снижаются в четверг после шестидневного ралли

Фондовые индексы стран Западной Европы опускаются в начале торгов в четверг, инвесторы ждут заседания Европейского центрального банка (ЕЦБ) и оценивают отчетность крупных европейских компаний.

Выбор редакции
Выбор редакции
25 апреля, 14:05

Why Is Inovio (INO) Down 2% Since the Last Earnings Report?

Inovio Pharmaceuticals (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

21 апреля, 14:12

Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

20 апреля, 16:53

AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.

17 апреля, 16:51

Рынок на $40 млрд: как фармгиганты инвестируют в лекарства от цирроза печени

Что привлекает игроков big pharma на рынке препаратов от неалкогольного стеатогепатита, где все еще нет ни одного официально одобренного лекарства?

13 апреля, 17:33

IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected

IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.

13 апреля, 14:36

Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

12 апреля, 15:21

5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

10 апреля, 16:29

Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

Выбор редакции
03 апреля, 16:50

AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

03 апреля, 16:39

Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance

Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.

Выбор редакции
31 марта, 14:21

Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.